BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7641411)

  • 21. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
    Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder.
    Melkersson K; Hulting AL
    Eur Arch Psychiatry Clin Neurosci; 2000; 250(1):6-10. PubMed ID: 10738858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ; Brownell J; Lamberts SW
    J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results.
    Jaspers C; Benker G; Reinwein D
    Clin Investig; 1994 Jun; 72(6):451-6. PubMed ID: 7950157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cabergoline and quinagolide therapy for prolactinomas.
    Webster J
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):549-50. PubMed ID: 11106914
    [No Abstract]   [Full Text] [Related]  

  • 32. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
    De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
    Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine Agonists: From the 1970s to Today.
    Auriemma RS; Pirchio R; De Alcubierre D; Pivonello R; Colao A
    Neuroendocrinology; 2019; 109(1):34-41. PubMed ID: 30852578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Quinagolide and macroprolactinomas a progress?].
    Jaquet P
    Ann Endocrinol (Paris); 1997; 58(2):83-5. PubMed ID: 9239225
    [No Abstract]   [Full Text] [Related]  

  • 35. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
    Colao A; Lombardi G
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2756. PubMed ID: 9253368
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of resistant prolactinomas.
    Olafsdottir A; Schlechte J
    Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
    Delgrange E; Donckier J
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2755-6. PubMed ID: 9253367
    [No Abstract]   [Full Text] [Related]  

  • 38. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of hyperprolactinemic anovulation with the dopamin-agonist quinagolide].
    Koloszár S; Keresztúri A; Kovács L
    Orv Hetil; 2000 Jul; 141(29):1621-3. PubMed ID: 10962898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.